On rotary tablet presses fitted with 10.5 mm round B-tooling and a force feeder, cobamamide at 0.5 mg per unit is processed as an ordered mixture rather than as a plain dry blend. The API fraction is first dispersed over a sacrificial layer of mannitol DC in a 60 L bin blender at 12 rpm for 15 min, then the preblend is added to a larger carrier matrix consisting of 145.0 mg mannitol DC, 30.0 mg microcrystalline cellulose, 4.0 mg crospovidone, and 2.0 mg magnesium stearate per tablet. Because the API mass represents less than 0.3% of the core weight, plain geometric dilution in a tumble blender without an intensifier bar yields detectable segregation during hopper vibration: industry-scale rotary press sampling has shown relative standard deviations exceeding 6% when force feeder paddle speed is raised above 30 rpm, while maintaining paddle speed at 18–22 rpm keeps blend RSD below 5.0% before lubrication. Compression force is adjusted to produce tablet hardness of 60–110 N; hardness below 50 N generates friability above 1.0% under Ph. Eur. 2.9.7, and hardness above 140 N extends disintegration beyond 15 min in 0.1 M hydrochloric acid at 37 °C. Dissolution is tracked with USP <711> Apparatus 2 at 50 rpm in 900 mL water; release samples are protected from ambient light and analysed by HPLC with UV detection at 260 nm, using a C18 column per USP <621>. Light shielding is mandatory throughout compression: direct illumination above 500 lux for more than 2 h on the feed frame converts cobamamide to hydroxocobalamin, so press windows are fitted with amber polycarbonate and inspection is performed under red LED. The terminal dosage form is an immediate-release tablet for oral administration, packed in aluminium/aluminium blisters with an oxygen absorbent because residual moisture above 2.0% w/w increases hydrolysis of the cobalt–carbon bond on long-term storage at 40 °C/75% RH.

What Limits Content Uniformity in a 0.5 mg Cobamamide Hard Capsule Filled on a Dosator Machine?

Low-dose hard capsule production shifts the primary risk from chemical degradation to mechanical segregation and electrostatic adhesion. For a size 3 hard gelatin capsule containing 0.5 mg cobamamide, the finished powder fill commonly consists of the API ordered onto 180–250 µm pregelatinized starch or mannitol carrier particles, with 1.0% sodium stearyl fumarate as lubricant; the use of magnesium stearate above 1.5% is avoided because over-lubrication reduces carrier surface adhesion and causes free API to accumulate in dead spaces of the capsule filler. On an intermittent-motion dosator machine, the powder plug is compressed inside a dosing tube at 10–30 N plug force; if the plug length drops below 8 mm, ejection forces increase and the plug may stick to the dosator pin, giving capsule weight variation outside ±5 mg. Tamping-pin fillers are less suitable for this API because repeated tamps generate dust that carries the low-mass API away from the carrier and deposits it on the capsule bushing. Weight variation is controlled at 120 mg ±5 mg, and content uniformity testing per USP <905> is run on 10 units at the start, middle, and end of the filling run; the acceptance value L1 must not exceed 15.0. Shell selection is a process control parameter: clear HPMC or gelatin capsules transmit visible light and are replaced by opaque red or brown shells when the product is not immediately overwrapped. Finished capsules are sealed and packed in PVC/PVDC-aluminium blisters; a moisture content above 2.0% in the fill or a gelatin shell exposed above 25 °C/60% RH causes shell deformation and powder leakage at the cap-body joint. In-line checkweighers with electromagnetic force restoration at 120 mg target mass provide 100% weight verification at 60 capsules per minute; off-line HPLC analysis per USP <621> quantifies cobamamide and the hydroxocobalamin degradation product with a reporting threshold of 0.1%. The terminal article is an oral hard capsule for single daily administration, with the capsule contents formulated to release cobamamide within 15 min in 900 mL water at 37 °C using USP <711> Apparatus 2.

Lyophilisation Cycle Design for Light-Sensitive Injectable Cobamamide

Aseptic processing of cobamamide for injection is dominated by two constraints: the aqueous solution loses potency under visible light, and the freeze-dried cake must avoid collapse during primary drying. For a lyophilised vial, the fill solution is prepared with 0.5 mg cobamamide, 25 mg mannitol, and 1.5 mg anhydrous citric acid adjusted to pH 6.0–6.5, filled at 1 mL into 3 mL Type I glass vials. The bulk solution is prepared under yellow light in an ISO 14644-1 Class C suite, filtered through 0.22 µm polyethersulfone membranes, and held for no more than 4 h before loading; extension of the hold time to 8 h generates measurable hydroxocobalamin at levels above 0.5% in the filtered bulk. The lyophilisation recipe uses a freezing ramp of 0.5 °C/min to −40 °C, followed by annealing at −10 °C for 2 h to promote mannitol crystallisation; amorphous mannitol levels above 2% w/w lower the collapse temperature and produce a cracked cake during primary drying. Primary drying is run at a shelf temperature of −20 °C and a chamber pressure of 100–150 mTorr for 18–24 h; a Pirani gauge reading that converges with the capacitance manometer reading indicates the end of ice sublimation, after which the shelf temperature is ramped to 25 °C at 0.2 °C/min and the pressure is reduced to 50 mTorr for secondary drying. The target residual moisture is <2.0% by Karl Fischer titration; vials with moisture above 3.0% show cake shrinkage and increased related substances after 6 months at 25 °C/60% RH. Because terminal steam sterilisation at 121 °C would destroy the cobalt–carbon bond, the dosage form is sterilised by aseptic filtration and lyophilisation, with media fill validation under FDA 21 CFR 211.113(b). Elemental impurities are controlled per ICH Q3D, and residual solvents are limited per ICH Q3C. The terminal product is reconstituted with 1 mL water for injection to give an intramuscular or intravenous injection; the reconstituted solution is used immediately and protected from direct light.

Sachet-based oral granules require a dry granulation route because aqueous wet massing introduces a cobalt–carbon hydrolysis pathway that cannot be reversed by drying. A dry granulation process using a roller compactor with knurled rolls at 4–8 kN/cm pressure converts a preblend of 0.5 mg cobamamide, 900 mg mannitol, 50 mg low-substituted hydroxypropyl cellulose, and 20 mg sodium carboxymethyl starch per sachet into flakes with a true density of 1.35–1.50 g/cm³; the flakes are milled through a 0.8 mm screen and sieved to retain particles between 150 µm and 500 µm. The granule size range is selected so that dissolution in 50 mL water at 25 °C produces a uniform suspension within 2 min without settling of the API-rich fraction; particles below 150 µm increase dust emissions and may carry disproportionate cobamamide into the sachet seal area, causing seal contamination and leakage. The sachet material is a 12 µm polyester/ 9 µm aluminium foil/ 60 µm low-density polyethylene laminate; oxygen transmission rate is specified below 0.5 cm³/m²·day·atm and water vapour transmission rate below 0.5 g/m²·day to protect the API. Filling is performed on a vertical form-fill-seal machine equipped with an auger filler calibrated to deliver 1.0 g ±2% per sachet; the auger speed is limited to 40 rpm to prevent shearing-induced particle attrition, and the seal jaws are set to 140–160 °C for polyethylene melt fusion without overheating the granule bed. Content uniformity of the filled sachets is assessed using Ph. Eur. 2.9.40, and related substances are limited to 2.0% total by HPLC per USP <621>. The finished dosage form is an oral granule for reconstitution, intended for patients who cannot swallow tablets or capsules; the reconstituted suspension has a pH between 5.5 and 6.5 to maintain the organometallic bond through the administration window.

When Cobamamide Is Combined with Benfotiamine and Pyridoxine in a Film-Coated Neurotropic Tablet

Combining cobamamide with benfotiamine and pyridoxine hydrochloride in a single film-coated core creates a segregation and degradation control problem that is not present in monotherapy tablets. Benfotiamine is hydrophobic and tends to segregate toward the top of a dry blend during bin-to-press transfer, while pyridoxine hydrochloride is water-soluble and can initiate localised acidic microenvironments that destabilise the cobalt–carbon bond; a two-stage granulation is therefore used in which benfotiamine is wet-granulated with 10% povidone K30 in isopropanol, and cobamamide is dry-manufactured separately on a mannitol carrier before both granulations are blended. A bilayer or multiparticulate core containing 0.5 mg cobamamide, 100 mg benfotiamine, and 100 mg pyridoxine hydrochloride is prepared with 60 mg microcrystalline cellulose and 4 mg crospovidone in the cobamamide layer. The two components are compressed on a rotary press with 8 mm round tooling and a main compression force of 8–12 kN; a pre-compression step at 2 kN is required to consolidate the benfotiamine granulation before the second layer is added, otherwise lamination occurs at the interface and the tablet splits during pan coating. Residual isopropanol is controlled to not more than 5000 ppm under ICH Q3C. Aqueous film coating is preferred for environmental control, but the coating pan inlet air temperature is held at 55–60 °C and the bed temperature is maintained below 45 °C; bed temperatures above 50 °C for more than 30 min increase the hydroxocobalamin content in the coated tablet above 1.0%. A PVA-based film coat containing iron oxide red or yellow at 3% w/w solids is applied to a weight gain of 3–4%; this coloured barrier reduces light-induced degradation, but the coated tablets are still packed in aluminium/aluminium blisters because visible light transmission through a 30 µm clear PVC blister is sufficient to produce measurable loss after 7 days at 25 °C under 4000 lux. Dissolution testing for the combination product follows USP <711> using 900 mL of 0.1 M hydrochloric acid at 37 °C; the cobamamide release is quantified by a stability-indicating HPLC method with a limit of quantitation of 0.05% of label claim. The terminal product is an oral film-coated tablet for neurotropic therapy, with the three active ingredients delivered from separate physical compartments to prevent interaction during storage.

Orally disintegrating tablets containing cobamamide are manufactured by direct compression at low compaction forces, and the principal processing conflict is between achieving adequate mechanical strength and preserving rapid wetting. The formulation uses 0.5 mg cobamamide dispersed on 100 mg mannitol DC and 30 mg microcrystalline cellulose, with 8 mg crospovidone as superdisintegrant and 2 mg magnesium stearate; compression is carried out on a hydraulic press or a rotary press with O-tooling at 2–4 kN, producing a tablet hardness of 20–35 N. At hardness above 40 N, the disintegration time in 50 mL water at 37 °C exceeds 30 s, which fails the typical orally disintegrating tablet acceptance criterion; at hardness below 15 N, the tablet breaks during push-through blister opening. Because cobamamide is hygroscopic, the powder blend is conditioned to 20–25 °C and 35–45% RH before compression; relative humidity above 60% causes the mannitol carrier to soften and the tablet to stick to the punch faces, while humidity below 20% increases electrostatic charging and content uniformity loss. The finished tablets are packed in moisture-impermeable aluminium peelable blisters with desiccant; a residual moisture above 1.5% w/w after 6 months at 40 °C/75% RH is associated with darkening and an increase in cyanocobalamin-related by-products. Friability is measured per Ph. Eur. 2.9.7 and must not exceed 1.0%; content uniformity is tested per USP <905> with an acceptance value L1 not exceeding 15.0. The terminal article is an orally disintegrating tablet that disintegrates in the oral cavity without water and is then swallowed, providing a ready-to-administer alternative for patients with dysphagia.